CellPoint enables clinicians to treat hematological malignancies by retargeting patient immune cells at the point-of-care.
In 2022, CellPoint was acquired by Galapagos, a fully integrated biotechnology company. Since then, they have been united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life. As a result, we will be sharing all company updates, news, and insights on the Galapagos’ page as of now.
Please follow Galapagos to stay updated on our latest developments and join our vibrant community. This page will stay online for cv referencing and historic purposes but will not be used to communicate updates. For details on the acquisition, please read our press release from 22 June 2022: https://www.glpg.com/press-release/3637/galapagos-to-acquire-cellpoint-and-aboundbio-to-accelerate-access-to-next-generation-cell-therapies
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
What industry is CellPoint in?
CellPoint operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is CellPoint based?
CellPoint is headquartered in Oegstgeest, Netherlands.
Find investors for your startup like CellPoint
Gritt sends AI-personalised outreach to each investor — from your Gmail
